Clinical trial NCT03106155: Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification
Official title: Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2017-04-10
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Vistusertib monotherapy (50 mg BID per os every 12 hours)
Primary purpose: TREATMENT

Brief summary: \[Study Design\] This study is a single arm, multi-center phase II study of vistusertib monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring RICTOR amplification. Patients will receive vistusertib monotherapy (50 mg BID per os every 12 hours) until they demonstrate objective disease progression or they meet any other discontinuation criteria.

\[Primary Objective\] To investigate the efficacy of vistusertib monotherapy in patients with relapsed SCLC patients harboring RICTOR amplification as 2nd or 3rd line therapy


Eligibility criteria: \[Inclusion Criteria\]

* Provision of informed consent prior to any study specific procedures
* Men and women aged at least 18 years
* Small cell lung cancer harboring RICTOR amplification
* Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no deterioration over the previous 2 weeks
* Minimum life expectancy of 12 weeks
* Patients must have acceptable bone marrow, liver and renal function measured within 14 days prior to administration of study treatment as defined below:
* At least one measurable lesion that can be accurately assessed by imaging or physical examination at baseline and follow up visits.
* No history of non-autologous bone marrow transplant.

Exclusion Criteria:

* Participation in another clinical study with an investigational product during the last 21 days.
* Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents within 21 days of starting study treatment. Prior use of an investigational monoclonal antibody therapy within 3 months.
* Major surgery within 4 weeks prior to study entry (excluding placement of vascular access), or minor surgery (excluding tumour biopsies) within 14 days of first dose of study treatment.
* Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP if taken within the stated washout periods before the first dose of study treatment (see Appendix 1)
* Exposure to specific substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within the appropriate wash-out period
* Any haemopoietic growth factors within 14 days prior to receiving study treatment.
* Pre-treatment with other PI3K, AKT, dual PI3K/mTRO and mTOR inhibitors
* Spinal cord compression and/or brain metastases unless asymptomatic or treated and stable off steroids for at least 4 weeks prior to start of study treatment.

Primary outcomes:
measure: Objective reponse rate (ORR) by RECIST 1.1
timeFrame: Up to 20 months
Secondary outcomes:
measure: Duration of response
timeFrame: Up to 20 months
measure: Disease control rate
timeFrame: at 12 weeks
measure: Overall survival (OS)
timeFrame: Up to 20 months
measure: Progression-free survival (PFS)
timeFrame: Up to 20 months
measure: Number of participants with Adverse Events as Assessed by CTCAE v4.03
timeFrame: Up to 20 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical center
Study officials:
References: